Future Research on Subarachnoid Hemorrhage: Guilherme Dabus, MD
The codirector of interventional neuroradiology and vice-chief of the department of neuroscience at Baptist Health Miami Neuroscience Institute discussed the questions that still remain with identifying and treating subarachnoid hemorrhage. [WATCH TIME: 3 minutes]
WATCH TIME: 3 minutes
Aneurysmal subarachnoid hemorrhage (SAH), a severely morbid and often deadly condition, is a significant global public health threat. Prehospital mortality rates from SAH have been reported to be between 22% and 26%, with these figures potentially rising in the coming years as the population continues to age. These persistently high in-hospital and prehospital mortality rates and increased incidence in the aging population call for improved therapies and practice standards in the management of patients with SAH.
Earlier this year, several notable experts in the field published new guidelines recommendations for the management of SAH, replacing the previous guidelines from 2012. Among the take-home messages noted, the first included improving timely and equitable access to health care system resources such as comprehensive stroke centers to improve overall patient outcomes. Additionally, the guidelines stressed that centers that comprise of dedicated neurocritical care units, experience with higher case volumes, and physician expertise in aneurysm treatment lead to lower mortality and increased likelihood of good functional outcomes.
The guidelines also direct clinicians to useful approaches to detect cerebral vasospasm and predict delayed cerebral ischemic, 2 significant complications of SAH. These include diagnostic modalities, including transcranial Doppler, computed tomography angiography, and computed tomography perfusion, as well as continuous electroencephalography and invasive monitoring.
NeurologyLive® recently sat down with
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025